Preclinical studies including panel of HER2+ BC cell lines and mouse models accentuated the benefit of dual targeting of mTOR and Src, where in combination, the recurrence of tumor growth following the treatment cessation is further delayed (Park et al., 2012; Yori et al., 2014). Here, SRC is linked to breast cancer.